Stay updated with breaking news from Context Therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76. Lehr...
ASCO 2023 Spotlight: Claudin 6 Anticipated To Shine
Context Therapeutics Inc. (NASDAQ:CNTX – Get Rating) – Investment analysts at HC Wainwright issued their Q1 2023 earnings per share (EPS) estimates for Context Therapeutics in a research note issued on Thursday, March 23rd. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright […]
HC Wainwright downgraded shares of Context Therapeutics (NASDAQ:CNTX – Get Rating) from a buy rating to a neutral rating in a report issued on Thursday morning, The Fly reports. HC Wainwright also issued estimates for Context Therapeutics’ FY2027 earnings at ($0.30) EPS. Context Therapeutics Stock Performance Context Therapeutics stock opened at $0.62 on Thursday. The […]
HC Wainwright lowered shares of Context Therapeutics (NASDAQ:CNTX – Get Rating) from a buy rating to a neutral rating in a research note issued to investors on Thursday, The Fly reports. HC Wainwright also issued estimates for Context Therapeutics’ FY2027 earnings at ($0.30) EPS. Context Therapeutics Price Performance Shares of CNTX opened at $0.62 on […]